Roboligent

Cover Block

Attribute	Details
Company	Roboligent
Tagline	AI-powered mobile manipulator robots for manufacturing and healthcare, focusing on human-robot interaction and automation.
Headquarters	Austin, USA
Founded	2016
Stage	Seed
Business Model	Hardware + Software
Industry	Deeptech
Technology	Robotics
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Seed (total disclosed ~$1,110,000)

Links

• Website: https://www.roboligent.com
• LinkedIn: https://www.linkedin.com/company/roboligent

Summary and Signal

Roboligent is a Texas-based robotics company developing AI-powered mobile manipulator robots designed to work safely alongside humans, a proposition that merits investor attention due to its focus on solving acute labor shortages in both healthcare and manufacturing through a single, versatile force-control technology [Roboligent website]. Founded in 2016 as LinkDyn Robotics, the company initially targeted automated physical therapy before expanding its platform to address industrial tasks like warehousing and assembly [CB Insights]. Its core differentiation lies in a proprietary force-controlled, or "soft," robotics system that enables safe human-robot interaction, which is commercialized through two main products: the ROBIN mobile dual-arm humanoid for industrial automation and the REGEN (Optimo Regen) robot for clinical rehabilitation [Roboligent website, June 2024].

Founder and CEO Bongsu Kim holds a Ph.D. in Robotics from the University of Texas at Austin, grounding the company's technical roadmap in academic research [Crunchbase]. To date, Roboligent has raised approximately $1.11 million in a mix of equity and non-dilutive grants from a consortium that includes Goseong Engineering, AFWERX, and the National Science Foundation [CB Insights]. The business model combines hardware sales with software for task management, targeting high-value automation in sectors where precision and safety are paramount. Over the next 12-18 months, the key indicators to monitor are the progression of announced proof-of-concept projects for ROBIN into paid commercial deployments and the establishment of named healthcare partners for the REGEN system.

Data Accuracy: YELLOW -- Core company facts are confirmed by the corporate website and Crunchbase; funding totals are reported by a single source (CB Insights) with some variance.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Deeptech
Technology Type	Robotics
Geography	North America
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Seed (total disclosed ~$1,110,000)

Company Overview

Roboligent operates as a lean, founder-led robotics venture from Austin, Texas, having navigated a decade-long development arc from academic research to a dual-market commercial focus. The company was incorporated in 2016 under the name LinkDyn Robotics [Crunchbase], [CB Insights].

The founder, Bongsu Kim, holds a Ph.D. in Robotics from the University of Texas at Austin, with prior graduate research completed at KAIST [Crunchbase]. A key operational milestone was the 2024 corporate minority investment led by Goseong Engineering [CB Insights]. The company's public identity and product branding also evolved during this period, culminating in the launch of its flagship platforms, ROBIN and REGEN [Roboligent website].

Headcount remains small, with third-party estimates pointing to a team of approximately five employees [Explorium]. LinkedIn profiles confirm a handful of technical and operational roles, including a Head of Operations and a Robotics AI/ML Engineer [LinkedIn, retrieved 2026].

Data Accuracy: YELLOW -- Core facts like founding year, founder background, and recent funding are confirmed by multiple sources, but specific operational milestones and team size are based on limited public corroboration.

The Product and the Stack

Roboligent’s product strategy is built on a single, versatile hardware and software platform, deployed across two distinct application suites. The company’s core technology is a mobile manipulator robot, branded as ROBIN, which serves as the physical base for both industrial and healthcare automation [Roboligent website]. The platform’s defining characteristic is its focus on compliant, force-controlled robotic arms, a technology often described as “soft robotics” that is designed for safe physical interaction with human workers and patients [Roboligent website]. This force-control capability, combined with an autonomous mobile base, imitation-learning software for task acquisition, and fleet management tools, forms the technical foundation for all current products [Roboligent website].

The company has commercialized this platform in two primary directions. For industrial and logistics settings, ROBIN is positioned as a general-purpose mobile manipulator. For healthcare, the platform is adapted into a specialized medical device called REGEN, also referred to as Optimo Regen [Roboligent website, Explorium].

Public details on the technical stack are limited to high-level descriptions from the company’s materials. The system integrates mobile navigation, dual-arm manipulation, and AI for task learning. The software layer appears to support teleoperation, allowing users to remotely control the robot for complex or hazardous tasks [Roboligent website]. The company has stated that ROBIN is currently undergoing proof-of-concept projects in various domestic and international settings [Roboligent website].

Data Accuracy: YELLOW -- Product claims are sourced directly from the company website and third-party aggregators, but detailed technical specifications and independent performance validations are not publicly available.

The Market They Are Entering

Roboligent's dual-market strategy targets two sectors where automation is a response to structural labor shortages and rising quality-of-care standards.

The company's primary wedge appears to be in robotic-assisted rehabilitation. According to a 2024 report from Grand View Research, the global medical robotics market was valued at $12.1 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 17.5% from 2024 to 2030 [Grand View Research, 2024].

For its industrial applications, Roboligent targets logistics, warehousing, and advanced assembly. The International Federation of Robotics reported that shipments of collaborative robots grew by 15% in 2023 [International Federation of Robotics, 2024].

Metric	Value
Medical Robotics Market (2023)	12.1 $B
Projected CAGR (2024-2030)	17.5 %
Collaborative Robot Shipment Growth (2023)	15 %

Data Accuracy: YELLOW -- Market sizing is based on analogous, third-party industry reports. Roboligent's specific target segment sizes are not publicly confirmed.

The Competitive Field

Roboligent operates at the intersection of two distinct but overlapping competitive arenas: specialized medical rehabilitation robots and general-purpose mobile manipulators for industrial settings.

In medical rehabilitation, the competitive set includes large incumbent medical device manufacturers with established sales channels and regulatory expertise, such as Hocoma (a DIH International company) with its Lokomat and Armeo systems, and smaller innovators like Ekso Bionics. Roboligent's REGEN/Optimo Regen is positioned as a more versatile, force-controlled platform for automating a range of physical therapy exercises [Roboligent website, "REGEN"].

The industrial and logistics segment pits Roboligent's ROBIN platform against established collaborative robot (cobot) arms from Universal Robots and Mobile Industrial Robots (MiR), as well as emerging mobile manipulators from companies like Boston Dynamics (Stretch) and newer startups. ROBIN's differentiator is its combination of a mobile base, dual compliant arms, and imitation-learning for task acquisition.

Data Accuracy: YELLOW -- Competitive positioning inferred from product claims and market segments; no direct competitor names or funding comparisons are publicly cited.

Opportunity

Roboligent's opportunity rests on the premise that its core technology, force-controlled robotics, can unlock a multi-billion dollar wedge across two of the most labor-constrained and automation-hungry sectors: manufacturing and healthcare.

Scenario	What happens	Catalyst	Why it's plausible
Therapeutic Standard-Bearer	REGEN/Optimo Regen becomes a standard piece of equipment in outpatient rehabilitation clinics.	A successful clinical evaluation study and a partnership with a major medical device distributor or rehab network.	The product is described as being on a "solid commercial route" with a collaborator for clinical use [Roboligent website, "REGEN"].
Industrial Automation Niche Dominance	The ROBIN platform wins a dominant share in a specific, high-mix, low-volume assembly or finishing niche.	Securing a flagship deployment with a known manufacturer in a sector like aerospace or electronics.	ROBIN is structured for "precise tasks" and is already in PoC projects in domestic and international settings [Roboligent website, "ROBIN"].

Data Accuracy: YELLOW -- Opportunity scenarios are extrapolated from cited product descriptions and market logic; specific catalyst details are not publicly confirmed.

Sources

1. [Roboligent website] Roboligent | Intelligent Manufacturing Automation | https://www.roboligent.com
2. [CB Insights] Roboligent - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/roboligent
3. [Roboligent website, June 2024] Revolutionizing Robotics: The Future with Roboligent | https://www.roboligent.com/post/revolutionizing-robotics-the-future-with-roboligent
4. [Crunchbase] Bongsu Kim - Founder, CEO @ Roboligent - Crunchbase Person Profile | https://www.crunchbase.com/person/bongsu-kim
5. [Explorium] Explorium company overview for Roboligent | https://www.explorium.ai/manufacturing/companies/roboligent
6. [LinkedIn, retrieved 2026] Roboligent | LinkedIn | https://www.linkedin.com/company/roboligent
7. [Grand View Research, 2024] Grand View Research report on medical robotics market | https://www.grandviewresearch.com/industry-analysis/medical-robotics-market
8. [International Federation of Robotics, 2024] International Federation of Robotics report on collaborative robot shipments | https://ifr.org/ifr-press-releases/news/cobot-market-shows-resilience